Evidence map›Paper›PMID 32987824›Full record

ArticleNutrients2020

Circulating Levels of the Soluble Receptor for AGE (sRAGE) during Escalating Oral Glucose Dosages and Corresponding Isoglycaemic i.v. Glucose Infusions in Individuals with and without Type 2 Diabetes.

Amelia K Fotheringham, Jonatan I Bagger, Danielle J Borg, Domenica A McCarthy, Jens J Holst, Tina Vilsbøll, Filip K Knop, Josephine M Forbes

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nutrients, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00529048 (Quantification of the Incretin Effect in Healthy Subjects and Patients With Type 2 Diabetes Using Increasing Amounts of Oral Glucose Challenges), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00529048 completednot on this map

Quantification of the Incretin Effect in Healthy Subjects and Patients With Type 2 Diabetes Using Increasing Amounts of Oral Glucose Challenges

TypeobservationalSponsorHerlev HospitalRan2007 to 2009Enrolled16ConditionsIncretin EffectArmsOral Glucose Tolerance Test, Isoglycemic clamp, Gastric emptying rate
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Plasma Levels of FreeNutrients · 2022
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Amelia K FotheringhamMater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia.ORCID 0000-0002-3213-8923
Jonatan I BaggerCenter for Clinical Metabolic Research, Herlev-Gentofte Hospital, University of Copenhagen, 2900 Hellerup, Denmark.ORCID 0000-0003-3174-1613
Danielle J BorgMater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia.ORCID 0000-0001-6126-7583
Domenica A McCarthyMater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia.
Jens J HolstNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.ORCID 0000-0001-6853-3805
Tina VilsbøllCenter for Clinical Metabolic Research, Herlev-Gentofte Hospital, University of Copenhagen, 2900 Hellerup, Denmark.
Filip K KnopCenter for Clinical Metabolic Research, Herlev-Gentofte Hospital, University of Copenhagen, 2900 Hellerup, Denmark.ORCID 0000-0002-2495-5034
Josephine M ForbesMater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia.
Translational Research Institute · AUUniversity of Copenhagen · DK

Funding

Investigator-Initiated Studies Program, Merck&Co., Inc no. 34851National Health and Medical Research Council GNT1102935
6 · The paper itself

Abstract

Postprandial glucose excursions are postulated to increase the risk for diabetes complications via the production of advanced glycation end products (AGEs). The soluble receptor of AGEs (sRAGE) likely acts as a decoy receptor, mopping up AGEs, diminishing their capacity for pro-inflammatory and pro-apoptotic signaling. Recent evidence suggests that AGEs and soluble receptor for AGEs (sRAGE) may be altered under postprandial and fasting conditions. Here, we investigated the effects of increasing oral glucose loads during oral glucose tolerance tests (OGTT) and matched isoglycaemic intravenous (i.v.) glucose infusions (IIGI) on circulating concentrations of sRAGE. Samples from eight individuals with type 2 diabetes and eight age-, gender-, and body mass index (BMI)-matched controls, all of whom underwent three differently dosed OGTTs (25 g, 75 g, and 125 g), and three matched IIGIs were utilised (NCT00529048). Serum concentrations of sRAGE were measured over 240 min during each test. For individuals with diabetes, sRAGE area under the curve (AUC

Indexed as

Administration, OralAgedBlood GlucoseBody Mass IndexDiabetes ComplicationsDiabetes Mellitus, Type 2FemaleGlucagon-Like Peptide 1GlucoseGlucose Tolerance TestHomeostasisHumansIncretinsMaleMiddle AgedReceptor for Advanced Glycation End ProductsBlood GlucoseGlucagon-Like Peptide 1GlucoseIncretinsReceptor for Advanced Glycation End ProductsAGEsdiabetes complicationsenteroendocrinemetabolic alterations of T2DMRAGEsRAGEtype 2 diabetes mellitus

Identifiers

PMID32987824
PMCPMC7598639
OpenAlexW3088113117

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.